Damian Marron
Vermögen: 12 021 $ am 31.08.2026
Vermögen: 12 021 $ am 31.08.2026
Dr. Damian Marron is a Chairman at Nicox SA, a Chairman at Circio Holding ASA, a Chairman at Indegra Therapeutics Ltd., a Chairman at Onya Therapeutics Ltd., a Head-Biopharma at Treehill Partners, LLC and a Non-Executive Chairman at Hone Bio Ltd. He is on the Board of Directors at Cantargia AB, Resolys Bio, Inc., Agalimmune Ltd. and Loxbridge Research LLP.
Dr. Marron was previously employed as an Independent Non-Executive Director by Bone Therapeutics SA, a Chief Executive Officer & Director by TxCell SA, a Chief Executive Officer by Trophos SA, a Head-European Business Development by Bausch & Lomb (Australia) Pty Ltd., a Director-Clinical Operations by Rhone-Poulenc Rorer BV, a Clinical Research Associate by Glaxo Wellcome Immobilière de Recherche SA, a Non-Executive Chairman by Cytheris SA, a Non-Executive Chairman by Imophoron Ltd., a Manager-Drug Group by Orphan Europe SARL, and a Chairman by PepGen Ltd. He also served on the board at France Biotech Association and Theralpha.
He received his undergraduate degree from The University of Liverpool.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CANTARGIA AB 0.02% | 31.12.2025 | 63’054 ( 0.02% ) | 12 021 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CIRCIO HOLDING ASA | Vorsitzender | 29.04.2020 |
| CANTARGIA AB | Direktor/Vorstandsmitglied | 26.05.2021 |
| NICOX SA | Vorsitzender | 16.07.2024 |
Agalimmune Ltd.
Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Develops anti-cancer immunotherapy technology | Direktor/Vorstandsmitglied | - |
Cytoseek Ltd.
Cytoseek Ltd. Miscellaneous Commercial ServicesCommercial Services Research and develops synthetic artificial membrane proteins | Vorsitzender | - |
Treehill Partners, LLC | Corporate Officer/Principal | - |
Resolys Bio, Inc.
Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company focusing on therapeutic agents for chronic disorders | Direktor/Vorstandsmitglied | 01.03.2018 |
Loxbridge Research LLP
Loxbridge Research LLP Financial ConglomeratesFinance Operates as an investment and project-management company | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| TXCELL | Vorstandsvorsitzender | 28.04.2015 |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░ | - |
| ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░░ ░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 21 |
|---|---|
Nicox SA
Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | Health Technology |
Trophos SA
Trophos SA Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention of neuronal loss for neurodegenerative diseases | Health Technology |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Commercial Services |
Orphan Europe SARL
Orphan Europe SARL Pharmaceuticals: MajorHealth Technology Develops and distributes orphan drugs for the treatment of rare diseases and metabolic disorders | Health Technology |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes prescription medicines | Health Technology |
Sangamo Therapeutics France SAS
Sangamo Therapeutics France SAS BiotechnologyHealth Technology Develops cellular immunotherapy platforms that treats severe inflammatory and autoimmune diseases | Health Technology |
Rhone-Poulenc Rorer BV | |
Glaxo Wellcome Immobilière de Recherche SA
Glaxo Wellcome Immobilière de Recherche SA Real Estate DevelopmentFinance Provides real estate services | Finance |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Bone Therapeutics SA
Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops regenerative therapy products for addressing unmet medical needs in the field of bone diseases and orthopedics | Health Technology |
Circio Holding ASA
Circio Holding ASA BiotechnologyHealth Technology Develops active immunotherapy cancer vaccines | Health Technology |
Theralpha | |
Loxbridge Research LLP
Loxbridge Research LLP Financial ConglomeratesFinance Operates as an investment and project-management company | Finance |
Agalimmune Ltd.
Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Develops anti-cancer immunotherapy technology | Health Technology |
Resolys Bio, Inc.
Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company focusing on therapeutic agents for chronic disorders | Commercial Services |
Cytoseek Ltd.
Cytoseek Ltd. Miscellaneous Commercial ServicesCommercial Services Research and develops synthetic artificial membrane proteins | Commercial Services |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Develops peptide drug delivery platform technology | Technology Services |
Treehill Partners, LLC | |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Develops a novel vaccine platform for use on emerging infectious diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen